Gut Microbiota as Potential Therapeutic Target for the Treatment of Cow’s Milk Allergy.

Cow's milk allergy (CMA) continues to be a growing health concern for infants living in Western countries. The long-term prognosis for the majority of affected infants is good, with about 80% naturally acquiring tolerance by the age of four years. However, recent studies suggest that the natural history of CMA is changing, with an increasing persistence until later ages. The pathogenesis of CMA, as well as oral tolerance, is complex and not completely known, although numerous studies implicate gut-associated immunity and enteric microflora, and it has been suggested that an altered composition of intestinal microflora results in an unbalanced local and systemic immune response to food allergens. In addition, there are qualitative and quantitative differences in the composition of gut microbiota between patients affected by CMA and healthy infants. These findings prompt the concept that specific beneficial bacteria from the human intestinal microflora, designated probiotics, could restore intestinal homeostasis and prevent or alleviate allergy, at least in part by interacting with the intestinal immune cells. The aim of this paper is to review what is currently known about the use of probiotics as dietary supplements in CMA

Efficacy of a partially hydrolyzed whey formula on infant colic: a randomized controlled trial

Background: Infant colic (IC) affects up to 20% of infants in the first 4 months of life. Although IC is a benign affection that spontaneously resolves after the first 3-4 months of life, it is often a stressful problem for parents. Methods: Babies, aged ≤ 3 months, observed at family pediatrician office because a suspect of IC, were randomized in two groups of 3-week dietary intervention: Group 1, receiving non-analgesic, non-nutritive soothing maneuvers, continuing a standard formula; Group 2, receiving a partially hydrolyzed whey formula (w-pHF), containing GOS (0.5g/100ml), low content of lactose (2.5g/100ml) and low osmolarity (185 mOsm). All infants performed clinical examinations at enrollment and after 7, 14 and 21 days. Number of colic episodes, and the number and consistency of fecal outputs were recorded daily. Results: Fifty infants with IC were enrolled and randomized: 25 in Group 1 and 25 in Group 2. The rate of infants with IC in Group 2 decreased significantly within 14 days compared to Group 1 and the number of bowel movements increased significantly within 7 days in Group 2 compared to Group 1. Stool consistency significantly improved in Group 2 within 7 days. Conclusion: The studied formula could represent a useful approach in infants with IC reducing pharmacological treatments

Radar array diagnosis from undersampled data using a compressed sensing/sparse recovery technique

A Compressed Sensing/Sparse Recovery approach is adopted in this paper for the accurate diagnosis of fault array elements from undersampled data. Experimental validations on a slotted waveguide test array are discussed to demonstrate the effectiveness of the proposed procedure in the failures retrieval from a small set of measurements with respect to the number of radiating elements. Due to the sparsity feature of the proposed formulation, the method is particularly appealing for the diagnostics of large arrays, typically adopted for radar applications

Efalizumab

Introduction: Conventional systemic therapies for psoriasis are associated with serious toxicities that can limit long-term use. In recent years, biological therapies have offered the possibility of long-term therapy with improved safety and efficacy for the treatment of psoriasis. Biological therapies can be classified into three categories: the T-cell modulating agents (alefacept and efalizumab), the inhibitors of TNF-alpha (adalimumab, etanercept, infliximab) and the inhibitors of IL-12 and -23 (ustekinumab). Efalizumab is a humanized recombinant monoclonal IgG1 antibody. It targets multiple stages in the immunopathogenesis of psoriasis: initial T-cell activation, migration of T-cells into dermal and epidermal tissues, and T-cell reactivation. On 19 February 2009, the Committee for Medicinal Products for Human Use (CHMP) recommended the suspension of the marketing authorisation for efalizumab.Areas covered: Numerous clinical trials have demonstrated the efficacy, safety and health-related quality of life benefits of efalizumab in patients with moderate-to-severe chronic plaque psoriasis. Efalizumab was approved by the FDA in November 2003 and by the European Medicines Evaluation Agency in September 2004 for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis. Recently, three cases of progressive multifocal leukoencephalopathy were described in patients on long-term (> 3 years) efalizumab therapy, leading to its withdrawal from the market.Expert opinion: Although initially favorable, the safety profile of efalizumab revealed the appearance of severe adverse events in long-term treated patients. Therefore, post-marketing surveillance is essential for correct evaluation of drug potential

The ATLAS Simulation: an LHC Challenge

The simulation program for the ATLAS experiment at CERN is currently in a full operational mode and integrated into the ATLAS common analysis framework, Athena. The OO approach, based on GEANT4, and in use during the DC2 data challenge has been interfaced within Athena and to GEANT4 using the LCG dictionaries and Python scripting. The robustness of the application was proved during the DC2 data challenge. The Python interface has added the flexibility, modularity and interactivity that the simulation tool requires in order to be able to provide a common implementation of different full ATLAS simulation setups, test beams and cosmic ray applications. Generation, simulation and digitization steps were exercised for performance and robustness tests. The comparison with real data has been possible in the context of the ATLAS Combined Test Beam (2004) and ongoing cosmic ray studies